|
 |
Nomes comerciais nos diversos países |
|
|
OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.
|
|
Bileco |
Argentina |
|
Blemisin |
Turquia |
|
Blenamax |
Colômbia, Eslovenia, Malásia |
|
Blenoxane |
Australia, Estados Unidos de América |
|
Bleocell |
Alemanha, Eslovenia |
|
Bleocin |
Arábia Saudita, Egipto, Emirados Árabes Unidos, Grècia, Japón, Malásia, México, Peru, Polonia, Portugal, Turquia |
|
Bleocip |
Egipto, Venezuela |
|
Bleocris |
Argentina, Peru |
|
Bleolem |
Colômbia, México |
|
Bleomax |
México |
|
Bleomedac |
Alemanha |
|
Bleomicina |
Chilli, Colômbia, Equator, Espanha, Itália, México, Peru |
|
Bleomycin |
Alemanha, Austria, Dinamarca, Estados Unidos de América, Finlandia, Gran-bretanha, Hungria, Irã, Islandia, Noruega, Países Baixos, Polonia, Romènia, Suècia |
|
Bleomycine |
Bélgica, Canadá, França, Irlanda, Luxemburgo, Malásia, Marrocos, nova Zelândia, Suicia |
|
Bloicin |
Egipto, Peru |
|
Blomindex |
México |
|
Blucin |
Marrocos |
|
Lyoble |
Peru |
|
Oncobleocin |
Colômbia |
|
|
 |
 |
Bibliografía : Bleomycin sulfate |
|
|
tipo |
publicação |
| 3 |
jornal |
Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212. |
| 81 |
jornal |
Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678. |
| 84 |
jornal |
Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499. |
| 99 |
jornal |
Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090. |
| 169 |
jornal |
Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363. |
| 182 |
jornal |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 56-60. |
| 244 |
jornal |
Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913. |
| 248 |
jornal |
Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304. |
| 249 |
jornal |
Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045. |
| 251 |
jornal |
Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713. |
| 252 |
jornal |
Koberda M, Zieske PA, Raghavan NV, Payton RJ.
Stability of bleomycin sulfate reconstituted in 5% dextrose injection or 0.9% sodium chloride injection stored in glass vials or polyvinyl chloride containers.
Am J Hosp Pharm 1990 ; 47: 2528-2529. |
| 307 |
jornal |
Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799. |
| 334 |
jornal |
Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992. |
| 335 |
jornal |
Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406. |
| 492 |
jornal |
Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189. |
| 905 |
jornal |
Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017. |
| 1410 |
jornal |
Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145. |
| 1423 |
jornal |
Trissel LA, Martinez JF, Gilbert DL.
Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 514-518. |
| 3128 |
Laboratório |
Mitomycine (Amétycine®) - Résumé Caractéristiques du Produit
Prostrakan 2013 |
| 3420 |
jornal |
El Kateb N, Chaussard M, Bellenger P, Petit A, Faure P.
Stability of an extemporaneously prepared bleomycin-lidocaine-epinephrine intradermal admixture used in dermatology
J Oncol Pharm Practice 2014 ; 21, 3: 178-187. |
| 3578 |
Laboratório |
Cisplatin - Summary of Product Characteristics
Accord Healthcare 2011 |
| 3644 |
Laboratório |
Calcium gluconate® - Summary of Product Characteristics
Hameln Pharmaceuticals 2010 |
| 3646 |
Laboratório |
Bléomycine sulfate (Bléomycine Bellon®) - Résumé des caractéristiques du produit
Sanofi Aventis France 2013 |
| 4154 |
Laboratório |
Bleomycin sulfate- Summary of Product Characteristics
Accord Health Care 2018 |
| 4471 |
Laboratório |
Amétycine 10 mg poudre pour solution injectable - Résumé des caractéristiques du produit - Oct 10, 2019
Kyowa Kirin Pharma 2019 |
| 4964 |
Laboratório |
GLUCONATE DE CALCIUM 10 % B.BRAUN, solution pour perfusion - Résumé des caractéristiques du produit.
B BRAUN MELSUNGEN AG 2019 |
| 5089 |
Laboratório |
Ascorbic Acid Injection 500mg/5ml - Summary of Product Characteristics Updated 04-Jan-2024 | Phoenix Labs
Phoenix Labs 2024 |
|
|
